UNIGE document Scientific Article
previous document  unige:13281  next document
add to browser collection

Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles

Bossy-Nobs, L.
Published in International Journal of Pharmaceutics. 2007, vol. 331, no. 2, p. 190-6
Abstract Two types of antibody-labeled nanoparticles (mAb-NPs) were prepared with the aim to achieve specific tumor targeting. Anti-HER2 and anti-CD20 monoclonal antibodies (mAb) were used as model ligands. Small poly(dl-lactic acid) nanoparticles (PLA NPs) with a mean size of about 170 nm were prepared by the salting out method. Thereafter, the coating of PLA NPs with mAbs was performed in two steps. First, thiol groups (-SH) were introduced on the surface of PLA-NPs by a two-step carbodiimide reaction. The number of -SH groups on the surface of NPs increased from 150 to 400 mmol-SH/mol PLA when cystamine concentrations of 25-1518 mol cystamine/mol PLA were used during the thiolation reaction. In the second step, covalent coupling of antibodies to thiolated NPs (NPs-SH) was obtained via a bifunctional cross-linker, m-maleimidobenzoyl-N-hydroxy-sulfosuccinimide ester (sulfo-MBS). For both mAbs anti-HER2 and anti-CD20, respectively, the number of -SH functions on the NPs had no influence on the amount of mAb coupled to the NPs. Approximately, 295 anti-HER2 and 557 anti-CD20 molecules, respectively, were covalently coupled per nanoparticle. The NPs size after the coupling reactions was about 250 nm. The specific interaction between tumor cells and mAb-NPs was determined by confocal microscopy using two cell lines: SKOV-3 human ovarian cancer cells (overexpressing HER2) and Daudi lymphoma cells (overexpressing CD20). The results showed the selective targeting of mAb-NPs to tumor cells overexpressing the specific antigen. While anti-CD20 labeled NPs (anti-CD20 NPs) bound to and remained at the cellular surface, anti-HER2 labeled NPs (anti-HER2 NPs) were efficiently internalized. The mAb-NPs represent a promising approach to improve the efficacy of NPs in active targeting for cancer therapy while the choice of the antibody-target system defines the fate of the mAb-NPs after their binding to the cells.
Keywords Antibodies, Monoclonal/administration & dosageAntibodies, Monoclonal, Murine-DerivedAntigens, CD20/immunologyAntineoplastic Agents/administration & dosage/chemistryCell Line, TumorCross-Linking ReagentsDrug Carriers/chemistryDrug Delivery Systems/methodsFemaleHumansImmunoconjugates/chemistryLactic AcidLymphoma/drug therapyNanoparticles/chemistry/therapeutic useOvarian Neoplasms/drug therapyPolymersReceptor, erbB-2/immunologySulfhydryl Compounds
PMID: 17196347
Full text
Article (Published version) (670 Kb) - document accessible for UNIGE members only Limited access to UNIGE
(ISO format)
CIRSTOIU, Adriana et al. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. In: International Journal of Pharmaceutics, 2007, vol. 331, n° 2, p. 190-6. https://archive-ouverte.unige.ch/unige:13281

159 hits

1 download


Deposited on : 2011-01-27

Export document
Format :
Citation style :